Great Point Partners’s Aurinia Pharmaceuticals AUPH Stock Holding History

Great Point Partners’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-175,000	Closed	-$2.42M	–	30
2020 Q4	$2.42M	Sell	175,000 -2,310,327	-93%	-$33.6M	0.39%	32
2020 Q3	$36.6M	Buy	+2,485,327	New	+$36M	3.29%	12
2017 Q2	–	Sell	-1,000,000	Closed	-$7.34M	–	40
2017 Q1	$7.34M	Buy	+1,000,000	New	+$4.62M	1.46%	23
2016 Q3	–	Sell	-2,457,144	Closed	-$7.19M	–	40
2016 Q2	$7.19M	Hold	2,457,144	–	–	2.06%	16
2016 Q1	$7.19M	Hold	2,457,144	–	–	2.58%	13
2015 Q4	$6.16M	Hold	2,457,144	–	–	2.59%	14
2015 Q3	$6.92M	Buy	2,457,144 +516,000	+27%	+$1.77M	2.74%	16
2015 Q2	$5.81M	Hold	1,941,144	–	–	2.27%	17
2015 Q1	$8.51M	Sell	1,941,144 -544,432	-22%	-$2.16M	3.75%	8
2014 Q4	$8.88M	Buy	2,485,576 +11,500	+0.5%	+$40.9K	4.28%	8
2014 Q3	$7.92M	Buy	+2,474,076	New	+$8.8M	3.4%	12

Other funds holding AUPH

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Great Point Partners's AUPH Position: Q1 2021 in Review

Great Point Partners sold out of Aurinia Pharmaceuticals (AUPH) in Q1 2021, closing a stake of 175,000 shares — an estimated $2.42M sold.

Great Point Partners first reported a position in AUPH in Q3 2014 and held it in 11 quarters. The position peaked at $36.6M in Q3 2020. 170 funds tracked by Wall St. Rank hold AUPH as of Q1 2021.

Great Point Partners reported no remaining Aurinia Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Great Point Partners sold 175,000 Aurinia Pharmaceuticals shares in Q1 2021, an estimated $2.42M.
Great Point Partners first reported a position in Aurinia Pharmaceuticals in Q3 2014 and held it in 11 quarters.
Great Point Partners's Aurinia Pharmaceuticals position peaked at $36.6M in Q3 2020.
170 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2021.

Based on Great Point Partners's 13F filing for Q1 2021, filed 17 May 2021.